Shares of Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB – Get Free Report) were down 14.6% during trading on Monday. The company traded as low as $0.9662 and last traded at $1.29. Approximately 222,458 shares traded hands during mid-day trading, an increase of 129% from the average daily volume of 97,071 shares. The stock had previously closed at $1.51.
Matinas Biopharma Trading Up 4.4%
The company has a market capitalization of $1.17 million, a price-to-earnings ratio of -0.07 and a beta of 2.24. The business’s 50 day moving average price is $2.41 and its two-hundred day moving average price is $6.86.
Matinas Biopharma (NYSEAMERICAN:MTNB – Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The company reported ($3.15) earnings per share (EPS) for the quarter.
Matinas Biopharma Company Profile
Matinas BioPharma Holdings, Inc is a clinical-stage biopharmaceutical company developing medicines based on its proprietary lipid nanocrystal (LNC) platform. The technology is designed to improve the delivery of pharmaceutical compounds, including drugs that may be difficult to administer through conventional oral formulations.
The company’s lead product candidate is MAT2203, an investigational oral formulation of amphotericin B, an antifungal medicine commonly administered intravenously.
See Also
- Five stocks we like better than Matinas Biopharma
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Matinas Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
